Moreover, they showed that both CD4+ and CD8+ T cells were involved in T-cell-mediated killing of CEA-positive tumor cells in agreement with previous data published by Kischel et al.68, 69, 70, 71 MEDI-565 is evaluated in three phase I studies in patients with GI adenocarcinomas (ClinicalTrials.gov: NCT01284231, NCT02291614, and NCT02760199). The gene discussed is CEACAM5; the disease is neoplasm.